2023
Awareness of racial/ethnic inequities in time to treatment among breast cancer providers.
Cohen I, Canavan M, Jacob A, Sondhi A, Silver H, Bramwell L, Lustberg M, Adelson K. Awareness of racial/ethnic inequities in time to treatment among breast cancer providers. JCO Oncology Practice 2023, 19: 584-584. DOI: 10.1200/op.2023.19.11_suppl.584.Peer-Reviewed Original ResearchBreast cancer providersCancer providersRace/ethnicityEthnic inequitiesTreatment inequitiesExact testSmilow Cancer HospitalYale Cancer CenterHospital-level factorsEducational interventionAdverse social determinantsFisher's exact testDe-identified databaseBrief educational interventionNon-Latinx WhitesPatient factorsWhite patientsProvider factorsCancer HospitalCancer CenterCancer patientsOncological careCare metricsClinical armTreatment metricsDexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)
Ruddy K, Zahrieh D, He J, Waechter B, Holleran J, Lewis L, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo H, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Seminars In Oncology 2023, 50: 7-10. PMID: 36693773, PMCID: PMC10247389, DOI: 10.1053/j.seminoncol.2023.01.001.Peer-Reviewed Original ResearchConceptsMTOR inhibitor-associated stomatitisDexamethasone mouthwashCoprimary endpointsTrough concentrationsExact testRandomized phase III trialEverolimus trough concentrationsPrior clinical researchPhase III trialsDose-limiting toxicityFisher's exact testMann-Whitney U testWilcoxon rank sum testRank sum testOral everolimusIII trialsOral stomatitisTreatment periodMouth rinseMTOR inhibitorsPoor enrollmentClinical researchEverolimusU testStomatitis
2021
Racial and ethnic disparities among patients with breast cancer and COVID-19.
Nagaraj G, Accordino M, French B, Kuderer N, Lyman G, Stover D, Blinder V, Schmidt A, Shatsky R, Grover P, Puc M, Hwang C, Wulff-Burchfield E, Lewis M, Menendez A, Bilen M, Warner J, Lustberg M, Shah D. Racial and ethnic disparities among patients with breast cancer and COVID-19. Journal Of Clinical Oncology 2021, 39: 6500-6500. DOI: 10.1200/jco.2021.39.15_suppl.6500.Peer-Reviewed Original ResearchCOVID-19 outcomesNon-Hispanic blacksNon-Hispanic whitesHospital admissionClinicopathologic characteristicsMechanical ventilationCancer characteristicsCOVID-19Laboratory-confirmed SARS-CoV-2Worse breast cancer outcomesIntensive care unit admissionCare unit admissionSevere COVID-19Breast cancer outcomesFisher's exact testSignificant differencesSARS-CoV-2High rateEthnic groupsCOVID-19 diagnosisAnti-cancer therapyRace/ethnicityActive diseaseUnit admissionBaseline characteristicsGenomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells